Long term toxicity of Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB)

Trial Profile

Long term toxicity of Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB)

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Giant cell tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Mar 2017 New trial record
    • 16 Mar 2017 Results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top